Amarin's Q2 revenue slides 42% to $42.2M, but deep cost cuts deliver positive cash flow and a brighter outlook
AMRN is trading near its 52-week low of $12.96 (9.3% above the low).
Summary
Amarin's Q2 revenue dropped 42% to $42.2M, but deep cost cuts delivered positive cash flow and a narrower loss. The company expects cash to grow ~10% by year-end, signaling self-sufficiency despite generic competition.
Key Events · Earnings and Guidance · AMRN
-
Revenue Down 42% on Tougher Comps
Total net revenue fell to $42.2M from $72.7M a year ago, largely because Q2 2025 included a $25M upfront licensing payment from Recordati. U.S. product sales slipped 12% to $32.2M on generic competition, partially offset by 14% branded prescription growth.
-
Cost Cuts Narrow Losses, Boost Cash
Operating expenses plunged 59% to $27.0M after completing a $70M annual savings plan. Net loss shrank to $7.65M from $14.1M, and cash rose to $314.6M — the third consecutive quarter of positive cash flow. Management expects ~10% cash growth by year-end 2026.
-
Global Demand and Market Share Improve
In-market demand for VASCEPA/VAZKEPA grew 59% year-over-year across partner markets, with Europe up 69%. U.S. IPE market share climbed to 48% from 43%, and the drug is now commercialized in 22 countries.
-
Restructuring Complete; Partnership Model Takes Hold
The global restructuring tied to the Recordati licensing deal is finished. The company is now operating under a fully partnered international model, which management says positions it for sustained profitability.
Analysis · AMRN · Life Sciences
Amarin's Q2 2026 results underscore a sharp 42% revenue decline to $42.2 million, driven by the absence of a one-time $25 million licensing payment from Recordati in the prior year and persistent generic pressure on U.S. VASCEPA sales. Yet the company's completed $70 million cost-savings program slashed operating expenses by 59%, narrowing the net loss from $14.1 million a year ago to $7.7 million. More importantly, Amarin generated positive cash flow for the third straight quarter and expects cash to grow ~10% by year-end, signaling the business can self-fund despite top-line headwinds. The 59% jump in global in-market demand and a 5-point gain in U.S. IPE market share to 48% suggest the underlying product franchise is stabilizing. Against a backdrop of recent legal setbacks and a failed shareholder vote on equity issuance, this earnings report provides a measure of financial resilience.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMRN was trading at $14.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $292.7M. The 52-week trading range was $12.96 to $20.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.